ThinkCyte
Founded Year
2016Stage
Series B | AliveTotal Raised
$41.4MLast Raised
$26M | 2 yrs agoAbout ThinkCyte
ThinkCyte develops Ghost Cytometry technology, a high-throughput image-based cell sorting system that integrates advanced imaging, machine learning, and microfluidics technologies. It enables researchers to identify cells based on their images and isolate target cells, including rare cells, in real-time. This approach brings throughput, analysis, and sorting on a single cell level to disciplines such as drug discovery, cell therapy, and clinical diagnostics.
ThinkCyte's Product Videos
ESPs containing ThinkCyte
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
These companies provide laboratory equipment and software to sequence, observe, and analyze individual cells. Solutions in this space enable pharma companies to develop therapies based on rare cellular genetics and phenotypes.
ThinkCyte named as Highflier among 15 other companies, including Mission Bio, Celsius Therapeutics, and HiFiBiO Therapeutics.
Compete with ThinkCyte?
Ensure that your company and products are accurately represented on our platform.
ThinkCyte's Products & Differentiators
VisionSort-CT
VisionSort-CT is a high-speed, high-content label-free analysis and sorting system using our proprietary GC technology for the manufacturing of cell therapy products including CAR-T, stem cells, etc. The product can be customized and used in various steps of the manufacturing processs, including QC, enrichment, and purification.
Expert Collections containing ThinkCyte
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
ThinkCyte is included in 8 Expert Collections, including Artificial Intelligence.
Artificial Intelligence
10,393 items
This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Medical Devices
8,633 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health Monitoring & Diagnostics
2,938 items
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
Digital Health
12,528 items
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Biopharma Tech
838 items
ThinkCyte Patents
ThinkCyte has filed 12 patents.
The 3 most popular patent topics include:
- Cell biology
- Flow cytometry
- Microscopy
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/2/2018 | 3/7/2023 | Norepinephrine, Molecular biology, Cell biology, T cells, Navigational equipment | Grant |
Application Date | 5/2/2018 |
|---|---|
Grant Date | 3/7/2023 |
Title | |
Related Topics | Norepinephrine, Molecular biology, Cell biology, T cells, Navigational equipment |
Status | Grant |
Latest ThinkCyte News
Mar 1, 2023
ThinkCyte Reveals VisionSort™ March 1, 2023 ThinkCyte, a biotechnology company pioneering novel artificial intelligence (AI)-based cell analysis, characterization, and isolation technologies, announced today that it will begin the commercial launch of its new cell sorting platform, VisionSort™. The launch coincides with the 2023 Society for Laboratory Automation and Screening (SLAS) conference in San Diego, CA from February 25-March 1, 2023 where VisionSort and its integrated Ghost Cytometry® technology were selected as finalists for Best New Product and Innovation Awards, respectively. The new ThinkCyte VisionSort is powered by Ghost Cytometry, an innovative AI-driven technology for characterizing and sorting cells based on their physical properties (morphology) and recognized by publication in the prestigious journal Science. It is the first cell sorter to combine analytical features found in conventional fluorescence flow sorters with the ability to perform label-free cell sorting and unbiased morphological analysis of cell populations. The combined capabilities can enable researchers to not only view cells based on a combination of known markers and morphological phenotypes, but also sort out unique populations for downstream processing or molecular analysis. “VisionSort is bringing an entirely new dimension to traditional cellular analysis and sorting,” said Janette Phi, Chief Business Officer at ThinkCyte. “By combining the ability to look at cellular morphology in 3-dimensions with traditional fluorescence measures and adding the power of AI to discover hidden patterns in data, VisionSort lets investigators view the relationship between cellular phenotypes and disease in completely new ways.” Access to the technology embedded in VisionSort was first announced last year through ThinkCyte’s Early Access Program. The EAP engaged participation from key biopharmaceutical industry partners and leading academic centers across a variety of application areas in cell therapy R&D, disease profiling, and drug discovery. One of these EAP partners will present new data on a novel approach at classification of leukemia patients using Ghost Cytometry at SLAS. More information about the ThinkCyte VisionSort cell sorter is available at the SLAS 2023 conference, through technical representatives at contact@thinkcyte.com, and at thinkcyte.com. previous post
ThinkCyte Frequently Asked Questions (FAQ)
When was ThinkCyte founded?
ThinkCyte was founded in 2016.
Where is ThinkCyte's headquarters?
ThinkCyte's headquarters is located at U. Tokyo Entrepreneur Plaza, Tokyo.
What is ThinkCyte's latest funding round?
ThinkCyte's latest funding round is Series B.
How much did ThinkCyte raise?
ThinkCyte raised a total of $41.4M.
Who are the investors of ThinkCyte?
Investors of ThinkCyte include SBI Investment, ITOCHU Technology Ventures, SPARX Group, Sysmex, Sumitomo Mitsui Trust Investment and 7 more.
Who are ThinkCyte's competitors?
Competitors of ThinkCyte include Luminex and 3 more.
What products does ThinkCyte offer?
ThinkCyte's products include VisionSort-CT and 1 more.
Who are ThinkCyte's customers?
Customers of ThinkCyte include Sysmex and Mid-size biotech.
Compare ThinkCyte to Competitors
Heroic-Faith is a Taiwan-based medical device developer that develops AI smart stethoscope using a miniature stethoscope with AI to discriminate and monitor breath sounds, which can be used in anesthesia breathing monitoring, breathing stop discrimination, home continuous breathing detection, and other situations.
AIndra Systems uses computer vision and deep learning to create a scalable, cloud-based solution for mobile facial recognition as well as tackling a wide array of problems in fields like enterprise healthcare and education. The platform also offers an automated and affordable 'point-of-sample collection' screening tool for cervical cancer. It was founded in 2012 and is based in Bengaluru, India.
GynTools offers a diagnostic system for vaginitis. It was founded in 2016 and is based in Jerusalem, Israel.
iAssay is a provider of point of care diagnostics solutions. The company provides an open platform for wirelessly connected point of care (POC) diagnostics. The device aggregates test, patient, and wearables data and pushes all data into the cloud. The aim is to eliminate test result delays, delayed diagnosis, sample handling and transportation costs. It also aim to improve patient outcomes and save the healthcare system money.
NanoPass Technologies develops and commercializes painless intradermal (skin) delivery solutions for vaccines and large molecules. NanoPass is continuously engaged in joint clinical development with top pharmaceutical companies, to demonstrate the benefits of its technology for various indications.
Senzo develops deep-technology biomedical testing products. It offers COVID-19 test products based on amplified lateral flow (ALF) technology and also integrates with flu testing, tuberculosis, human immunodeficiency virus (HIV), and hepatitis testing. It caters to the clinical testing industry. The company was founded in 2019 and is based in London, United Kingdom.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.